Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Codexis Inc (CDXS) operate in?
Codexis Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Codexis Inc (CDXS) current stock price?
As of the latest data, Codexis Inc stock price is $1.56, with a previous close of $1.60. Codexis Inc lost -$0.04 in the last trading session, representing a -2.5% loss.
What is Codexis Inc (CDXS) current market capitalization?
Codexis Inc market cap is approximately 167.80 million.
What is Codexis Inc (CDXS) Earnings Per Share (EPS)?
The trailing EPS is -$0.35, and the forward EPS is -$0.37.
What is Codexis Inc (CDXS) EBITDA?
Codexis Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.79 million.
Does Codexis Inc (CDXS) pay dividends?
No. Codexis Inc does not pay a dividend.
How did Codexis Inc (CDXS) perform in its most recent earnings report?
In the last report (June 30, 2026), Codexis Inc posted an EPS surprise of 23.53% and a revenue surprise of 7.89%.
What is Codexis Inc (CDXS) beta (volatility) score?
Codexis Inc has a beta of 2.504, indicating very high volatility compared to the market.
